Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 24, 2022 (5 years ago)

Chloresin

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

CHLORESIN (acetaminophen 325mg, dextromethorphan HBr 15mg, Guaifenesin 200mg, Phenylephrine HCl 5mg) 2 tablet packets, Manufactured For Afassco Inc. Minden NV 89423, NDC 51532-0107-2

Affected NDC 51532-0107-02

Compare with the code on your package — it is the most precise check available.

Drug: Phenylephrine Category: Pain Relief & OTC Medication

Recalling firm
Ultra Seal Corporation
NDC code
51532-0107-2
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0468-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Phenylephrine recalls

See all

Other recalls by Ultra Seal Corporation

All 2022 recalls
Class II · Moderate risk

Sinus Relief

cGMP deviations

Terminated cGMP deviation Ultra Seal Corporation D-0518-2022